Previous 10 | Next 10 |
home / stock / alxo / alxo articles
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an im...
Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an im...
U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday. Shares of United Airlines Holdings, Inc. (NASDAQ: UAL) rose ...
Over the past twenty days of trading, ALX Oncology Holdings Inc. (NASDAQ: ALXO), from February 09, 2024 to March 08, 2024 there is a potential Sho...
Thursday, ALX Oncology Holdings (NASDAQ:ALXO) reported a fourth-quarter 2023 EPS loss of $(0.93), missing the consensus of $(0.86). ...
- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANC...
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. AAR reported ...
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sh...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...
2024-05-10 08:30:07 ET H.C. Wainwright analyst issues BUY recommendation for ALXO on May 10, 2024 06:40AM ET. The previous analyst recommendation was Buy. ALXO was trading at $16.95 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...